Malignant mesothelioma: Facts, Myths, and Hypotheses

Journal of Cellular Physiology

Volumn 227, Issue 1, 2012, Pages 44-58

  Carbone, Michele ^a,b   Ly, Bevan H ^a   Dodson, Ronald F ^c   Pagano, Ian ^a   Morris, Paul T ^a,d   Dogan, Umran A ^e,f   Gazdar, Adi F ^g,h   Pass, Harvey I ⁱ   Yang, Haining ^a,b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Dodson Environmental Consulting   (United States)

^d QUEEN S MEDICAL CENTER   (United States)

^e IA United States   (United States)

^f KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CARCINOGEN; CHRYSOTILE; ERIONITE; ESTRADIOL; OXYGEN; REACTIVE NITROGEN SPECIES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GENETICS; CANCER MORTALITY; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; ENVIRONMENTAL EXPOSURE; GENDER; GENETIC PREDISPOSITION; HUMAN; INDUSTRIALIZATION; MACROPHAGE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MUTATION; NONHUMAN; OCCUPATIONAL CARCINOGENESIS; OCCUPATIONAL EXPOSURE; PERITONEUM MESOTHELIOMA; PLEURA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION EXPOSURE; RADIATION SAFETY; REVIEW; SIMIAN VIRUS 40; SYMPTOM; TRANSMISSION ELECTRON MICROSCOPY; UNITED STATES; VIRUS INFECTION;

HUMANS; MESOTHELIOMA;

EID: 80054885219     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22724     Document Type: Review

References (171)

1. Abratt RP, White NW, Vorobiof DA. 2005. Epidemiology of mesothelioma-A South African perspective. Lung Cancer 49:S13-S15.
2. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Cronin K, Chen H, Feuer E, Stinchcomb D, Edwards B. 2010. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute. based on November 2009 SEER data submission, posted to the SEER web site. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Cronin K, Chen H, Feuer E, Stinchcomb D, Edwards B, editors.
3. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR. 2005. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24:6080-6089.
4. Ampleford EJ, Ohar J. 2007. Mesothelioma: You do not have to work for it. Diagn Cytopathol 35:774-777.
5. Anderson HA, Lilis R, Daum SM, Fischbein AS, Selikoff IJ. 1976. Household-contact asbestos neoplastic risk. Ann NY Acad Sci 271:311-323.
6. Aoe K, Hiraki A, Murakami T, Toyooka S, Shivapurkar N, Gazdar AF, Sueoka N, Taguchi K, Kamei T, Takeyama H, Sugi K, Kishimoto T. 2006. Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan. Cancer Sci 97:292-295.
7. Ascoli V, Scalzo CC, Bruno C, Facciolo F, Lopergolo M, Granone P, Nardi F. 1998. Familial pleural malignant mesothelioma: Clustering in three sisters and one cousin. Cancer Lett 130:203-207.
8. Azuma K, Uchiyama I, Chiba Y, Okumura J. 2009. Mesothelioma risk and environmental exposure to asbestos. Int J Occup Health 15:166-172.
9. Baker PM, Clement PB, Young RH. 2005. Malignant peritoneal mesothelioma in women: A study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 123:724-737.
10. Bani-Hani KE, Gharaibeh KA. 2005. Malignant peritoneal mesothelioma. J Surg Oncol 91:17-25.
11. Baumann F, Rougier Y, Ambrosi JP, Robineau BP. 2007. Pleural mesothelioma in New Caledonia: An acute environmental concern. Cancer Detect Prev 31:70-76.
12. Berry G, Roger J, Pooley FD. 1989. Mesotheliomas. Asbestos exposure and lung burden. In: Bignon J, Peto J, Saracci R, editors. Non occupational exposure to mineral fibers. Lyon, France: IARC scientific publication No 90. pp 486-496.
13. Bertino P, Carbone M, Pass H. 2009. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother 10:99-107.
14. Bianchi C, Brollo A, Ramani L, Zuch C. 1993. Asbestos-related mesothelioma in Monfalcone, Italy. Am J Ind Med 24:149-160.
15. Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L. 2004. Familial mesothelioma of the pleura-A report of 40 cases. Ind Health 42:235-239.
16. Bianchi C, Bianchi T, Tommasi M. 2007. Long latency periods in asbestos-related mesothelioma of the pleura. Eur J Oncol 12:189-195.
17. Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, Pass HI, Rizzo P, Carbone M. 2000. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 97:10214-10219.
18. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. 2008. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 68:1022-1029.
19. Boffetta P. 2007. Epidemiology of peritoneal mesothelioma: A review. Ann Oncol 18:985-990.
20. Bourdes V, Boffetta P, Pisani P. 2000. Environmental exposure to asbestos and risk of pleural mesothelioma: Review and meta analysis. Eur J Epidemiol 16:411-417.
21. Boutin C, Dumortier P, Rey F, Villiat JR, De Vuyst P. 1996. Black Spots concentrate oncogenic asbestos fibers in the parietal pleura. Am J Respir Crit Care Med 153:444-449.
22. Britton M. 2002. The epidemiology of mesothelioma. Semin Oncol 29:18-25.
23. Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM. 1996. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 98:2050-2059.
24. Burki T. 2010. Health experts concerned over India's asbestos industry. Lancet 375:626-627.
25. Butnor KJ, Sporn TA, Hammar SP, Roggli VL. 2001. Well-differentiated papillary mesothelioma. Am J Surg Pathol 25:1304-1309.
26. Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, Gaudino G. 2001. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98:12032-12037.
27. Camidge DR, Stockton DL, Bain M. 2006. Factors affecting the mesothelioma detection rate within national and international epidemiological studies: Insights from Scottish linked cancer registry-mortality data. Br J Cancer 95:649-652.
28. Carbone M, Bedrossian CW. 2006. The pathogenesis of mesothelioma. Semin Diagn Pathol 23:56-60.
29. Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, Mew DJ, Levine AS, Procopio A. 1994. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9:1781-1790.
30. Carbone M, Kratzke RA, Testa JR. 2002. The pathogenesis of mesothelioma. Semin Oncol 29:2-17.
31. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, Baris YI. 2007a. A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes. Nat Rev Cancer 7:147-154.
32. Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand MC, Kjaerheim K, Pass HI, Robinson B, Tsao A. 2007b. Eighth International Mesothelioma Interest Group. Oncogene 26:6959-6967.
33. Carbone M, Pannuti A, Zhang L, Testa JR, Bocchetta M. 2008. A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells. Cancer Res 68:9488-9496.
34. Chao CC, Park SH, Aus E. 1996. Partecipation of nitric oxide and iron in the oxidation of DNA in asbestos-treated human ling epithelial cells. Arch Biochem Biophys 326:152-157.
35. Choe N, Tanaka S, Xia W, Hemenway DR, Roggli VL, Kagan E. 1997. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect 105:1257-1260.
36. Choe N, Tananaka S, Kagan E. 1998. Asbestos fibers and interleukin 1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol 19:226-236.
37. Chua TC, Yan TD, Morris DL. 2009a. Surgical biology for the clinician: Peritoneal mesothelioma: Current understanding and management. Can J Surg 52:59-64.
38. Chua TC, Yao P, Akther J, Young L, Bao S, Samaraweera U, Yan TD, Morris DL. 2009b. Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res 15:671-678.
39. Cicala C, Pompetti F, Carbone M. 1993. SV40 induces mesotheliomas in hamsters. Am J Pathol 142:1524-1533.
40. Connelly RR, Spirtas R, Myers MH, Percy CL, Fraumeni JF, Jr. 1987. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 78:1053-1060.
41. Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakov K, Minor P, Carbone M. 2005. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res 65:10273-10279.
42. Dawson A, Gibbs AR, Pooley FD, Griffiths DM, Hoy J. 1993. Malignant mesothelioma in women. Thorax 48:269-274.
43. Daya D, McCaughey WT. 1990. Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 65:292-296.
44. de Klerk NH, Armstrong BK, Musk AW, Hobbs MS. 1989. Cancer mortality in relation to measures of occupational exposure to crocidolite at Wittenoom George in Western Australia. Br J Ind Med 46:529-536.
45. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M. 2006. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207-215.
46. Dodoli D, Del Nevo M, Fiumalbi C, Iaia TE, Cristaudo A, Comba P, Viti C, Battista G. 1992. Environmental household exposures to asbestos and occurrence of pleural mesothelioma. Am J Ind Med 21:681-687.
47. Dodson RF, Williams MG, Corn CJ, Brollo A, Bianchi C. 1990. Asbestos content of lung tissue, lymph nodes and pleural plaques from former shipyard workers. Am Rev Respir Dis 142:843-847.
48. Dodson RF, O'Sullivan M, Corn C, McLarty JW, Hammar SP. 1997. Analysis of asbestos fi{ligature}ber burden in lung tissue from mesothelioma patients. Ultrastruct Pathol 21:321-336.
49. Dodson RF, O'Sullivan M, Huang J, Holiday DB, Hammar SP. 2000. Asbestos in extrapulmonary sites omentum and mesentery. Chest 117:486-493.
50. Dodson RF, O'Sullivan M, Brooks DR, Bruce JR. 2001. Asbestos content of omentum and mesentery in nonoccupationally exposed individuals. Toxicol Ind Health 17:138-143.
51. Dodson RF, Atkinson MAL, Levin JL. 2003a. Asbestos fiber length as related to potential pathogenicity: A critical review. Am J Ind Med 44:291-297.
52. Dodson RF, O'Sullivan M, Brooks DR, Hammar SP. 2003b. Quantitative analysis of asbestos burden in women with mesothelioma. Am J Ind Med 43:188-195.
53. Dodson RF, Graef R, Shepherd S, O'Sullivan M, Levin JL. 2005. Asbestos burden in cases of mesothelioma from individuals from various regions of the United States. Ultrastruct Pathol 29:415-433.
54. Dodson RF, Shepherd S, Levin J, Hammar SP. 2007. Characteristics of the asbestos concentration in various levels of lymph nodes that collect drainage from the lung. Ultrast Pathol 31:95-153.
55. Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. 2006. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66:5063-5068.
56. Doll R. 1955. Mortality from lung cancer in asbestos workers. Br J Ind Med 12:81-86.
57. Driece HA, Siesling S, Swuste PH, Burdorf A. 2010. Assessment of cancer risks due to environmental exposure to asbestos. J Expo Sci Environ Epidemiol 20:478-485.
58. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. 1999. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6-12.
59. Epler GR, Fitz Gerald MX, Gaensler EA, Carrington CB. 1980. Asbestos-related disease from household exposure. Respiration 39:229-240.
60. Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. 2007. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect 115:1401-1405.
61. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. 2008. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg 135:620-626.
62. Fresco R. 2005. Malignant mesothelioma electron microscopy. In: Pass HI, Vogelzang NJ, Carbone M, editors. Malignant mesothelioma advances in pathogenesis, diagnosis, and translational therapies. New York: Springer Science+Business Media, Inc. pp 508-516.
63. Gazdar AF, Butel JS, Carbone M. 2002. SV40 and human tumours: Myth, association or causality? Nat Rev Cancer 2:957-964.
64. Goldberg M, Imbernon E, Rolland P, Ilg AGS, de Quillacq A, Frenay C, Chamming's S, Arveux P, Boutin C, Pairon JC, Astoul P, Galateau-Sallé F, Brochard P. 2006. The French National Mesothelioma Surveillance Program. Occup Environ Med 63:390-395.
65. Goodman JE, Nascarella MA, Valberg PA. 2009. Ionizing radiation: A risk factor for mesothelioma. Cancer Causes Control 20:1237-1254.
66. Gorovenko GG, Slepukha IM, Kogosov Iu A, Mezhibovskii Iu G. 1986. Pleural mesothelioma after therapeutic artificial pneumothorax. Vrach Delo 6:54-56.
67. Griffiths MH, Riddell RJ, Xipell JM. 1980. Malignant mesothelioma: A review of 35 cases with diagnosis and prognosis. Pathology (Phila) 12:591-603.
68. Heintz NH, Janssen-Heininger YM, Mossman BT. 2010. Asbestos, lung cancers, and mesotheliomas: From molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42:133-139.
69. Heller DS, Gordon RE, Clement PB, Turnnir R, Katz N. 1999. Presence of asbestos in peritoneal malignant mesotheliomas in women. Int J Gynecol Cancer 9:452-455.
70. Hershcovici T, Chajek-Shaul T, Hasin T, Aamar S, Hiller N, Prus D, Peleg H. 2006. Familial Mediterranean fever and peritoneal malignant mesothelioma: A possible association. Isr Med Assoc J 8:501-511.
71. Hesdorffer ME, Chabot J, DeRosa C, Taub R. 2008. Peritoneal mesothelioma. Curr Treat Options Oncol 9:180-190.
72. Hillerdal G. 1983. Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 77:321-343.
73. Hillerdal G. 1999. Mesothelioma: Cases associated with non-occupational and low dose exposures. Occup Environ Med 56:505-513.
74. Hillerdal T, Berg J. 1985. Malignant mesothelioma secondary to chronic inflammation and old scars. Cancer 55:1968-1972.
75. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR. 2009. Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133:1317-1331.
76. Ilgren EB, Pooley FD, Larragoitia JC, Talamantes M, Navarrete GL, Krauss E, Brena AF. 2008. First confirmed erionite related mesothelioma in North America. Indoor Built Environ 17:567-568.
77. Ishak GE, Khoury NJ, Birjawi GA, El-Zein YR, Naffaa LN, Haddad MC. 2006. Imaging findings of familial Mediterranean fever. Clin Imaging 30:153-159.
78. Ismail-Khan R, Robinson LA, Williams CC, Jr., Garrett CR, Bepler G, Simon GR. 2006. Malignant pleural mesothelioma: A comprehensive review. Cancer Control 13:255-263.
79. Iwatsubo Y, Matrat M, Michel E, Boutin C, Galateau-Salle F, Jougla E, Bignon J, Pairon JC, Brochard P. 2002. Estimation of the incidence of pleural mesothelioma according to death certificates in France. Am J Ind Med 42:188-199.
80. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. 2006. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66:352-361.
81. Jemal A, Grauman D, Devesa S. 2000. Recent geographic patterns of lung cancer and mesothelioma mortality rates in 49 shipyard counties in the United States, 1970-94. Am J Ind Med 37:512-521.
82. Jimenez LA, Zanella C, Fung H, Janssen YM, Vacek P, Charland C, Goldberg J, Mossman BT. 1997. Role of extra cellular signal regulated protein kinases in apoptosis by asbestos and H2O2. Am J Physiol 273:L1029-L1035.
83. Kielkowski D, Nelson G, Rees D. 2000. Risk of mesothelioma from exposure to crocidolite asbestos: A 1995 update of a South African mortality study. Occup Environ Med 57:563-567.
84. Kliment CR, Clemens K, Oury TD. 2009. North American erionite-associated mesothelioma with pleural plaques and pulmonary fibrosis: A case report. Int J Clin Exp Pathol 2:407-410.
85. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, Ramos-Nino M, Mossman BT, Pass HI, Carbone M. 2006. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103:14128-14133.
86. Krousel T, Garcas N, Rothschild H. 1986. Familial clustering of mesothelioma: A report on three affected persons in one family. Am J Prev Med 2:186-188.
87. Kurumatani N, Kumagai S. 2008. Mapping the risk of mesothelioma due to neighborhood asbestos exposure. Am J Respir Crit Care Med 178:624-629.
88. Lagnese JA. 2002. Economic aspects of meothelioma. In: Pass HI, Vogelzang N, Carbone M, editors. Malignant mesothelioma, advances in pathogenesis, adiagnosis and translational therapies. New York: Springer Science+Business Media, Inc. pp 821-832.
89. LeBouffant L. 1980. Physics and chemistry of asbestos dust. In: Wagner JC, editor. Biological effects of mineral fibres. Lyon, France: IARC Scientific Publications. pp 15-33.
90. Leigh J, Davidson P, Hendrie L, Berry D. 2002. Malignant mesothelioma in Australia 1945-2000. Am J Ind Med 41:188-201.
91. Li FP, Lokich J, Lapey J, Neptune WB, Wilkins EW, Jr. 1978. Familial mesothelioma after intense asbestos exposure at home. JAMA 240:467.
92. Lieben J, Pistawka H. 1967. Mesothelioma and asbestos exposure. Arch Environ Health 14:559-5563.
93. Liu JY, Brass DM, Hoyle GW, Brody AR. 1998. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 153:1839-1847.
94. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. 2004. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364:1157-1166.
95. Low J, Humes HD, Szczypka M, Imperiale M. 2004. BKV and SV40 infection of human kidney tubular epithelial cells in vitro. Virology 323:182-188.
96. Machida N, Tanaka R, Takemura N, Fujii Y, Ueno A, Mitsumori K. 2004. Development of pericardial mesothelioma in golden retrievers with a long term history of idiopathic haemorrhagic pericardial effusion. J Comp Pathol 131:166-175.
97. Magnani C, Terracini B, Ivaldi C, Botta M, Budel P, Mancini A, Zanetti R. 1993. A cohort study on mortality among wives of workers in the asbestos cement industry in Casale Monferrato, Italy. Br J Ind Med 50:779-784.
98. Magnani C, Terracini B, Ivaldi C, Botta M, Mancini A, Andrion A. 1995. Pleural malignant mesothelioma and non-occupational exposure to asbestos in Casale Monferrato, Italy. Occup Environ Med 52:362-367.
99. Magnani C, Agudo A, Gonzalez CA, Andrion A, Calleja A, Chellini E, Dalmasso P, Escolar A, Hernandez S, Ivaldi C, Mirabelli D, Ramirez J, Turuguet D, Usel M, Terracini B. 2000. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br J Cancer 83:104-111.
100. Magnani C, Dalmasso P, Biggeri A, Ivaldi C, Mirabelli D, Terracini B. 2001. Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: A case-control study in Casale Monferrato, Italy. Environ Health Perspect 109:915-919.
101. Magner D, McDonald AD. 1972. Malignant mesothelial tumors-Histologic type and asbestos exposure. N Engl J Med 287:570-571.
102. Maher B. 2010. Fear in the dust. Nature 468:884-885; and Editorial, 2010. Asbestos scandal. Nature 468:868.
103. Marchevsky AM, Harber P, Crawford L, Wick MR. 2006. Mesothelioma in patients with nonoccupational asbestos exposure. An evidence-based approach to causation assessment. Ann Diagn Pathol 10:241-250.
104. McDonald AD, McDonald JC. 1980. Malignant mesothelioma in North America. Cancer 46:1650-1656.
105. Merler E, Roberti S. 2008. A population-based study on Radiotherapy (RT) as a risk factor for Malignant Mesothelioma (MM). The 9th International Conference of the International Mesothelioma Interest Group. p 116.
106. Miller A. 2005. Mesothelioma in household members of asbestos-exposed workers: 32 United States cases since 1990. Am J Ind Med 47:458-462.
107. Mitchev K, Dumortier P, DeVuyst P. 2002. "Black spots" and hyaline pleural plaques on the parietal pleura of 150 Urban Necropsy cases. Am J Surg Pathol 25:1198-1206.
108. Mitha R, Pooley FD. 1993. Determination of asbestos in lung tissue using transmission electron microscopy. IARC Sci Publ 109:190-195.
109. Moolgavkar SH, Meza R, Turim J. 2009. Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes Control 20:935-944.
110. Muller K-M, Schmitz I, Konstantinidis K. 2002. Black spots of the parietal pleura: Morphology and formal pathogenesis. Respiration 69:261-267.
111. Murai Y. 2001. Malignant mesothelioma in Japan: Analysis of registered autopsy cases. Arch Environ Health 56:84-88.
112. Musk AW, Dolin PJ, Armstrong BK, Ford JM, de Klerk NH, Hobbs MS. 1989. The incidence of malignant mesothelioma in Australia, 1947-1980. Med J Aust 150:242-243, 246.
113. Musti M, Cavone D, Aalto Y, Scattone A, Serio G, Knuutila S. 2002. A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. Cancer Genet Cytogenet 138:73-76.
114. Nakamura E, Makishima A, Hagino K, Okabe K. 2009. Accumulation of radium in ferruginous protein bodies formed in lung tissue: Association of resulting radiation hotspots with malignant mesothelioma and other malignancies. Proc Jpn Acad Ser B Phys Biol Sci 85:229-239.
115. Nicholson WJ. 1983. Tumour incidence after asbestos exposure in the USA: Cancer risk of non-occupational population. Report nr VDI-Report No. 475. 161-177pp.
116. Olofsson K, Mark J. 1989. Specificity of asbestos-induced chromosomal aberrations in short-term cultured human mesothelial cells. Cancer Genet Cytogenet 41:33-39.
117. Ordonez NG. 1998. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 22:1203-1214.
118. Ordonez NG. 2006. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 19:34-48.
119. Ordonez NG. 2007. Pathologic characterization and differential diagnosis of malignant peritoneal mesothelioma. Recent Results Cancer Res 169:123-136.
120. Pan XL, Day HW, Wang W, Beckett LA, Schenker MB. 2005. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 172:1019-1025.
121. Paoletti L, Falchi M, Batisti D, Zappa M, Chellini E, Biancalani M. 1993. Characterization of asbestos fibers in pleural tissue from 21 cases of mesothelioma. Med Lav 84:373-378.
122. Paoletti L, Batisti D, Bruno C, Di Paola M, Gianfagna A, Mastrantonio M, Nesti M, Comba P. 2000. Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: An epidemiological and environmental study. Arch Environ Health 55:392-398.
123. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. 2005. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564-1573.
124. Patel AV, Bogner PN, Klippenstein D, Ramnath N. 2008. Malignant pleural mesothelioma after household exposure to asbestos. J Clin Oncol 26:5480-5483.
125. Percy C, Stanek E III, Gloeckler L. 1981. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 71:242-250.
126. Peto J, Doll R, Hermon C, Binns W, Clayton R, Goffe T. 1985. Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg 29:305-355.
127. Picklesimer AH, Zanagnolo V, Niemann TH, Eaton LA, Copeland LJ. 2005. Case report: Malignant peritoneal mesothelioma in two siblings. Gynecol Oncol 99:512-516.
128. Pietruska JR, Kane AB. 2007. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 67:3637-3645.
129. Pinheiro GA, Antao VC, Bang KM, Attfield MD. 2004. Malignant mesothelioma surveillance: A comparison of ICD 10 mortality data with SEER incidence data in nine areas of the United States. Int J Occup Environ Health 10:251-255.
130. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. 2009. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 69:4598-4604.
131. Price B, Ware A. 2009. Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39:576-588.
132. Quinlan TR, BeruBe KA, Hacker MP, Taatjes DJ, Timblin CR, Goldberg J, Kimberley P, O'Shaughnessy O, Hemenway D, Torino J, Jimenez LA, Mossman BT. 1998. Mechanisms of asbestos-induced nitric oxide production by rat alveolar macrophages in inhalation and in vitro models. Radic Biol Med 24:778-788.
133. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA, Mossman BT. 2008. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 38:209-217.
134. Ribak J, Lilis R, Suzuki Y, Penner L, Selikoff IJ. 1991. Death certificate categorization of malignant pleural and peritoneal mesothelioma in a cohort of asbestos insulation workers. J Soc Occup Med 41:137-139.
135. Risberg B, Nickels J, Wagermark J. 1980. Familial clustering of malignant mesothelioma. Cancer 45:2422-2427.
136. Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. 2008. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med 14:316-321.
137. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F, Robinson BW, Lake RA. 2006. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: Malignant transformation is dose dependent. Cancer Res 66:10786-10794.
138. Rodelsperger K, Jockel KH, Pohlabeln H, Romer W, Woitowitz HJ. 2001. Asbestos and man made vitreous fibers as risk factors for diffuse malignant mesothelioma: Results from a german hospital based case control study. Am J Ind Med 39:262-275.
139. Roe FJ, Carter RL, Walters MA, Harington JS. 1967. The pathological effects of subcutaneous injections of asbestos fibres in mice: Migration of fibres to submesothelial tissues and induction of mesotheliomata. Int J Cancer 2:628-638.
140. Roggli VL, Oury TD, Moffatt EJ. 1997. Malignant mesothelioma in women. Anat Pathol 2:147-163.
141. Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. 2002. Malignant mesothelioma and occupational exposure to asbestos: A clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26:55-65.
142. Ross D, McDonald JC. 1995. Occupational and geographical factors in the epidemiology of malignant mesothelioma. Monaldi Arch Chest Dis 50:459-463.
143. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. 2001. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357:444-445.
144. Schneider J, Woitowitz HJ. 1995. Asbestos-related mesotheliomas in housewives from indoor air pollution. Zentralbl Hyg Umweltmed 196:495-503.
145. Schneider J, Straif K, Woitowitz HJ. 1996. Pleural mesothelioma and household asbestos exposure. Rev Environ Health 11:65-70.
146. Sebastien P, Jason X, Gaudichet A, Hirsch A, Bignon J. 1980. Asbestos retention in human respiratory tissues: Comparative measurements in lung parenchyma and in parietal pleura. In: Wagner JC, editor. Biological effects of mineral fibers. Lyon: IARC. pp 237-246.
147. Sebbag G, Sugarbaker PH. 2001. Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol 27:223-224.
148. Selikoff IJ. 1992. Use of death certificates in epidemiological studies, including occupational hazards: Discordance with clinical and autopsy findings. Am J Ind Med 22:469-480.
149. Selikoff IJ, Hammond EC, Seidman H. 1979. Mortality experience of insulation workers in the United States and in Canada 1943-1976. Ann NY Acad Sci 330:91-96.
150. Shanks JH, Harris M, Banerjee SS, Eyden BP, Joglekar VM, Nicol A, Hasleton PS, Nicholson AG. 2000. Mesotheliomas with deciduoid morphology: A morphologic spectrum and a variant not confined to young females. Am J Surg Pathol 24:285-294.
151. Shia J, Erlandson RA, Klimstra DS. 2002. Deciduoid mesothelioma: A report of 5 cases and literature review. Ultrastruct Pathol 26:355-363.
152. Sluis-Cremer GK. 1991. Asbestos disease at low exposures after long residence times. Ann NY Acad Sci 643:182-193.
153. Sluis-Cremer GK, Liddell FDK, Logan WPD, Bezuidenhout BN. 1992. The mortality of amphibole miners in South Africa, 1946-80. Br J Ind Med 49:566-575.
154. Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, Harlow BL, Benichou J. 1994. Malignant mesothelioma: Attributable risk of asbestos exposure. Occup Environ Med 51:804-811.
155. Stratton K, Alamario DA, McCormick MC. 2003. Immunization safety review SV40 contamination of polio vaccine and cancer. Washington, DC: The National Academies Press.
156. Sugarbaker DJ. 2008. Pleural MM as a second primary cancer post therapeutic radiation for Hodgkin's and non Hodgkin's disease. The 9th international conference of the International Mesothelioma Interest Group. p 115.
157. Suzuki Y, Yuen RS, Ashley R. 2005. Short, thin asbestos fibers contribute to the development of malignant mesothelioma: Pathological evidence. Int J Hyg Environ Health 208:201-210.
158. Tan E, Warren N, Darnton AJ, Hodgson JT. 2010. Projections of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer 103:430-436.
159. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley FD, Rizzo P, Rusch V, Xiao GH. 1998. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58:4505-4509.
160. Tweedale G, McCulloch J. 2004. Chrysophiles versus chrysophobes: The white asbestos controversy, 1950s-2004. Isis 95:239-259.
161. Vianna NJ, Polan AK. 1978. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1:1061-1063.
162. Wagner JC, Sleggs CA, Marchand P. 1960. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260-271.
163. Wagner JC, Skidmore JW, Hill RJ, Griffiths DM. 1985. Erionite exposure and mesotheliomas in rats. Br J Cancer 51:727-730.
164. Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ, Nishimura SL, Gordon GJ, Broaddus VC. 2008. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 39:576-583.
165. Xu A, Wu LJ, Santella RM, Hei TK. 1999. Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells. Cancer Res 59:5922-5926.
166. Xu A, Zhou H, Yu DZ, Hei TK. 2002. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: Implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect 110:1003-1008.
167. Yan TD, Popa E, Brun EA, Cerruto CA, Sugarbaker PH. 2006. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 93:1536-1542.
168. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M. 2006. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103:10397-10402.
169. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. 2010. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107:12611-12616.
170. Zanella CL, Timblin CR, Cummins A, Jung M, Goldberg J, Raabe R, Tritton TR, Mossman BT. 1999. Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fos and apoptosis. Am J Physiol 277:L684-L693.
171. Ziegler A, Seemayer CA, Hinterberger M, Vogt P, Bigosch C, Gautschi O, Tornillo L, Betticher DC, Moch H, Stahel RA. 2007. Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung Cancer 57:282-291.